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Recent evidence suggests that a subset of cancer cells within some tumors, the so-called 
cancer stem cells, may drive the growth and metastasis of these tumors. Understanding 
the pathways that regulate proliferation, self-renewal, survival, and differentiation of malig-
nant and normal stem cells may shed light on mechanisms that lead to cancer and suggest 
better modes of treatment.The need for cells to proliferate 
over the life span of an organism 
may place individuals at risk in 
the numbers game that underlies 
cancer. Adult stem cell lineages 
may have evolved to lower this 
risk by minimizing the chance of 
cells escaping the mechanisms 
that restrict their expansion. 
There is emerging evidence that 
some blood cell cancers and solid 
tumors may contain a cancer cell 
hierarchy reminiscent of the nor-
mal tissue in which the malignan-
cies first arose, with a cancer stem 
cell producing progeny with lim-
ited replication potential (Al-Hajj 
et al., 2003; Lapidot et al., 1994; 
Singh et al., 2004). For example, in 
tumors of the breast and brain, a 
minority population of cancer stem 
cells have the ability to self-renew, 
whereas the majority of cancer 
cells have limited or no ability to 
proliferate. This suggests that can-
cer stem cells may drive the growth 
and spread of the tumor. The pres-
ence of a stem cell population in 
a tumor has implications for the 
diagnosis and treatment of can-
cer, as it is these cancer stem cells 
that must be targeted to achieve 
a cure. Failure to eliminate these 
self-renewing cells sets the stage 
for the regrowth of a tumor follow-
ing cessation of chemotherapy. 
The ability to prospectively iden-
tify cancer stem cells will allow the 
investigation of key molecules and 
pathways that could be targeted to 
eliminate these malignant cells. Key steps in the progression to 
cancer may involve failure of nor-
mal developmental mechanisms 
evolved by long-lived multicellu-
lar organisms to meet the needs 
for renewing short-lived cell types 
such as those of the skin, gut, and 
blood. Cancers often arise in tissues 
such as skin, gut, and blood where 
constant proliferation is required to 
ensure a continued supply of newly 
differentiated cells. Replacement of 
the mature cells in these tissues is 
accomplished by a highly orches-
trated process in which a relatively 
small population of self-renewing 
adult stem cells gives rise to prolif-
erating progenitor cells (sometimes 
called transit-amplifying cells) that 
undergo limited rounds of mitotic 
division and then terminally differen-
tiate, losing their ability to proliferate 
further (see Figure 1A). In this hier-
archical system, only the stem cells 
are long-lived. Indeed, although 
progenitor cells have some ability to 
replicate, their life span as prolifer-
ating cells is short, often measured 
in days or weeks.
Key Properties of Tissue  
Stem Cells
The remarkable longevity of tissue 
stem cells relies on their unique abil-
ity to undergo self-renewing mitotic 
divisions in which one or both prog-
eny retain the stem cell identity and 
the capacity to replicate almost 
indefinitely. The daughters of stem 
cell divisions also have the option 
to follow a differentiation pathway. Cell 124, MThe balance between self-renewal 
and differentiation must be strictly 
regulated to maintain the stem cell 
pool and to generate the required 
supply of fully differentiated cells 
needed for tissues to carry out their 
many tasks.
Stem cells in adult tissues must 
produce large numbers of differ-
entiated progeny. These transit-
amplifying progenitor cells may 
undergo a limited series of mitotic 
cycles, sometimes referred to as 
transit-amplifying cell divisions, 
before entering a postmitotic fully 
differentiated state (see Figure 1A). 
In this way, the activity of a rela-
tively small number of stem cells 
can be amplified to produce large 
numbers of differentiated progeny. 
For example, in the male germline 
or the bone marrow (both of which 
contain well-studied stem cell pop-
ulations), a relatively small number 
of germline or hematopoietic stem 
cells produce billions of sperm or 
mature blood cells over the life of 
the individual.
Did Stem Cells Evolve as a 
Protection against Cancer?
The evolution of single-cell organ-
isms into multicellular animals with 
their specialized cell types and 
complex organ systems neces-
sitated development of strict con-
trols to keep cellular proliferation 
in check. If any cells in the tissue 
community shake loose from these 
constraints on proliferation, then the 
resulting tumor can kill the individ-arch 24, 2006 ©2006 Elsevier Inc. 1111
Figure 1. The Possible Origins of 
 Cancer Stem Cells
(A) Interactions between normal stem cells 
and the tissue stroma (niche). In normal tis-
sues, the niche cells (pale green) provide 
signals enabling normal stem cells (blue) to 
self-renew (curved arrow). Transit-amplify-
ing progenitor cells (pink, yellow, orange) do 
not receive this signal and their proliferation 
is constrained by cellular mechanisms that 
count the number of mitotic divisions. With 
each cell division, the proliferation capacity 
of these daughter cells declines (programmed 
decline in replication potential), and their de-
gree of differentiation increases. Panels B, 
C, and D represent possible ways in which 
tumors may arise from normal stem cells by 
circumventing niche-dependent restrictions 
on stem cell expansion. 
(B) Expansion of the stem cell niche (pale 
green) allows a corresponding expansion of 
cancer stem cells (dark pink) that have arisen 
from normal stem cells. The expansion of 
niche cells may be driven by alterations in the 
cancer stem cells or in the niche cells them-
selves. In either case, there is an expansion of 
the self-renewing cancer stem cell pool that 
gives rise to aberrantly differentiated but non-
tumorigenic cancer cells, which comprise the 
bulk of the tumor. 
(C) Alterations in cancer stem cells (dark pink) 
enable them to commandeer alternative niche 
cells (dark green) to provide them with self-
renewal signals. This mechanism could result 
in the invasion of local tissues or may facilitate 
cancer stem cell growth at sites of metasta-
sis. Again, the resultant tumors are a mixture 
of cancer stem cells and their nontumorigenic 
progeny. 
(D) Genetic or epigenetic alterations in cancer 
stem cells enable them to become niche-in-
dependent such that they undergo cell-au-
tonomous self-renewal generating tumors 
containing self-renewing stem cells and their 
nontumorigenic progeny, which make up the 
bulk of the tumor. It is possible that progres-
sion from niche dependence to independence 
is common during the progression of a neo-
plasm to a more aggressive tumor. 
(E) Mutations may arise that imbue transit-
amplifying progenitor cells with the stem 
cell property of self-renewal. Further genetic 
events in this pool of abnormally self-renew-
ing cells culminates in a malignancy. In this 
example of self-renewal, the cancer stem cell 
is derived not from a normal stem cell but from 
one of its partially differentiated progeny.ual organism. Long-lived multicel-
lular organisms have evolved many 
fail-safe mechanisms to protect 
them against developing cancer. 
As a result, progression to cancer 
requires that a number of mutations 
accumulate in the same cell lineage 
in order to collectively circumvent 
these protective mechanisms. For 1112 Cell 124, March 24, 2006 ©2006 Elexample, progression to cancer 
may involve loss of normal growth 
controls leading to the formation 
of polyps, or the inactivation of the 
fail-safe mechanisms that com-
pel abnormal cells to die or that 
prevent cells from migrating into 
surrounding tissues (Fearon and 
Vogelstein, 1990). However, even sevier Inc.the requirement for a single cell 
to accumulate several mutations 
before it becomes cancerous may 
not be sufficient to prevent long-
lived organisms from dying of can-
cer at a relatively young age. Avoid-
ing cancer is essentially a numbers 
game. For example, trillions of cells 
are formed in the human body over 
a normal life span, and if all of the 
cells in the body retain the ability to 
divide, there would be a reasonable 
chance that at least one cell would 
accumulate sufficient mutations to 
become cancerous while the organ-
ism is still young. Thus, organisms 
have developed a strategy to limit 
the number of long-lived cells with 
self-renewal capacity. Restricted 
long-term renewal of short-lived 
cell types may reduce the chance 
that a single cell with proliferative 
capacity will accumulate the 
mutations required for malignant 
transformation.
The counting mechanisms that 
normally regulate and limit the 
number of rounds of successive 
transit-amplifying cell divisions may 
also provide an important safeguard 
against cancer. Although both stem 
cells and transit-amplifying cells 
divide and produce the same end-
products—a spectrum of differen-
tiating progeny—they differ in their 
ability to proliferate and maintain an 
undifferentiated state for an extended 
period of time. A single hematopoi-
etic stem cell (HSC) can regenerate 
the blood system of a mouse. By 
contrast, a transit-amplifying pro-
genitor cell, although descended 
from an HSC, cannot self-renew, and 
so, when transplanted into a lethally 
irradiated host, can only contribute 
to the blood system for a brief period 
of time (Morrison and Weissman, 
1994). With each cell division, the 
progeny of a hematopoietic transit-
amplifying cell become progressively 
more differentiated, with measurably 
reduced capacity to proliferate (see 
Figure 1A). This programmed decline 
in replication potential may help to 
guarantee that progenitor cells cease 
proliferation and terminally differen-
tiate before they have a chance to 
accumulate the multiple mutations 
that are required for tumor formation 
(see Figure 1A).
The Crucial Role of the Stem 
Cell Niche
Normal stem cells share many prop-
erties with cancer stem cells, most 
notably the trait of self-renewal. To 
maintain tissue homeostasis, the number of daughter cells that retain 
stem cell identity must be strictly 
controlled such that differentiated 
cells can be generated in response 
to, for example, wounding while the 
stem cell pool is simultaneously 
replenished but not expanded. By 
blocking expansion of the stem cell 
pool, stem cells are prevented from 
forming tumors.
The HSC is the best understood 
mammalian stem cell. Mouse genet-
ics has shown that the regulation of 
HSC number is under the control of 
multiple genes (Morrison et al., 2002). 
That multiple genes restrict unlimited 
stem cell expansion is logical con-
sidering that unregulated expansion 
of self-renewing cells would lead to 
either hyperplasia or a frank tumor. 
Emerging evidence indicates that a 
specialized microenvironment, the 
stem cell niche, is one of the factors 
regulating normal stem cell mainte-
nance and self-renewal. The stem cell 
niche controls stem cell maintenance 
and the crucial choice between self-
renewal and the initiation of differen-
tiation (Spradling et al., 2001). Thus, 
stem cells appear to require para-
crine signals from the cellular niche 
in which they reside to maintain their 
identity and self-renewal capacity. 
As a result, the number of stem cells 
within a particular tissue can be reg-
ulated by controlling the number or 
size of available niches.
The best understood examples of 
regulation of stem cell self-renewal 
by the niche are to be found in the 
female and male germline stem cells 
of the fruit fly Drosophila (Yamashita 
et al., 2005). In both male and female 
reproductive tissues, a small number 
of somatic support cells provides a 
microenvironment that maintains 
the germline stem cells. Indeed, the 
niche cells are the source of mol-
ecules that activate signal transduc-
tion pathways in the germline stem 
cells specifying maintenance of stem 
cell fate. The stem cells physically 
attach to the niche and, when they 
divide, orient their mitotic spindles 
with respect to the niche, so that one 
daughter inherits the attachment and 
stays in the niche, whereas the other 
daughter is displaced away from the Cell 124, Mniche and activates expression of 
genes that launch this cell along the 
differentiation pathway (Chen and 
McKearin, 2003; Kiger et al., 2000, 
2001; Tulina and Matunis, 2001; Xie 
and Spradling, 2000; Yamashita et 
al., 2003). Additional layers of regu-
lation may ensure that the response 
to the niche signal is local and that 
the daughter cell displaced from the 
niche is able to follow a developmen-
tal fate that is different from that of 
its sibling remaining in the niche. The 
mechanisms that shape the different 
pathways followed by the two daugh-
ter cells are not yet fully understood. 
However, such mechanisms may 
involve negative feedback loops that 
trigger either activation of repressors 
of the response to the self-renewal 
signal or physical isolation of the 
differentiating cell from the niche by 
enveloping guardian or escort cells 
(Decotto and Spradling, 2005; Kiger 
et al., 2000; Schulz et al., 2002). In 
the Drosophila female germline, 
where the regulatory circuitry from 
the signal to the key target in the 
stem cell has been worked out, the 
main role of the signal from the niche 
is to block expression of genes that 
trigger the onset of differentiation 
(Chen and McKearin, 2003; Xie and 
Spradling, 2000).
Recent studies suggest that cellu-
lar niches are important in prevent-
ing mammalian stem cell expansion 
(Calvi et al., 2003; Zhang et al., 2003). 
Certain key elements of the mecha-
nisms that specify self-renewal and 
prevent differentiation of stem cells in 
the niche may be conserved through 
evolution. These elements include 
paracrine signaling pathways, nega-
tive feedback loops that limit the 
response to mitogenic signals, and 
pathways that suppress activa-
tion of the differentiation program 
in stem cells. These suppression 
mechanisms include translational 
repression, as well as regulators of 
chromatin that repress expression 
of terminal differentiation genes in 
stem cells. A fail-safe mechanism 
is guaranteed by ensuring that dif-
ferentiation is the default state, that 
is, adult stem cells are programmed 
to differentiate and so are lost to the arch 24, 2006 ©2006 Elsevier Inc. 1113
pool of long-term proliferating cells 
unless they are located in a specific 
place within the niche.
Stem Cell Regulation and Cancer
Genes that program self-renewal 
rather than differentiation are likely 
to be candidate oncogenes. One of 
the best examples of such genes is 
Bmi1, a component of the Polycomb 
transcriptional silencing machinery 
that regulates transcription of target 
genes through epigenetic repression 
(Jacob et al., 1999). Studies in the 
adult mouse have shown that Bmi1 is 
required for the maintenance of HSCs 
and of neural stem cells (Molofsky 
et al., 2003; Park et al., 2003). The 
observation that active repression 
by Polycomb is needed for stem 
cell self-renewal suggests that, as in 
the Drosophila female germline, dif-
ferentiation is the default pathway. 
Thus, a stem cell is only able to suc-
cessfully maintain stem cell identity 
and self-renew when Bmi1 represses 
genes that promote differentiation or 
cell death.
The same molecular pathway that 
governs self-renewal in normal stem 
cells also seems to be usurped by 
cancer stem cells in leukemia and 
other malignancies. Emerging evi-
dence indicates that tumors may be 
maintained by a subset of cancer 
cells with stem-cell like properties 
that have the capacity to self-renew. 
These cancer stem cells prolifer-
ate indefinitely and presumably can 
seed new tumors in distant sites 
in the body. In a mouse model of 
leukemia, Bmi1 is required for con-
tinued proliferation and self-renewal 
of leukemia stem cells. When bone 
marrow cells of wild-type mice are 
infected with a retrovirus expressing 
both the HoxA9 and Meis1 genes—
both of which have been implicated 
in the development of acute leuke-
mia—the mice die from leukemia. 
Importantly, however, this outcome 
requires functional Bmi1. Although 
Bmi1 mutant mice infected with 
the retrovirus carrying the HoxA9 
and Meis1 genes exhibit leukemic 
blast cells in their bone marrow, the 
leukemia could not be transplanted 
to naïve secondary recipient animals 1114 Cell 124, March 24, 2006 ©2006 E(Lessard and Sauvageau, 2003). 
Thus, in the absence of Bmi1, the 
leukemic cells failed to self-renew 
and eventually stopped replicating.
Characterizing the crucial role 
of Bmi1 in stem cell maintenance 
should allow identification of other 
key regulators in this process. Genes 
that turn on expression of Bmi1 and 
the target genes that Bmi1 represses 
in stem cells may also be involved 
in self-renewal and in cancer. For 
example, Sonic hedgehog (Shh) sig-
naling, which has been implicated in 
the self-renewal of stem cells in both 
the brain and blood, can upregulate 
Bmi1 expression in primitive neural 
stem or progenitor cells (Leung et 
al., 2004). Likewise, proteins such 
as p19Arf, p16Ink4a, and Tp53, whose 
genes are negatively regulated by 
Bmi1, are tumor suppressors that 
may be components of the fail-safe 
mechanisms that block inappropri-
ate self-renewal in stem or progenitor 
cell lineages.
Cancer in Stem Cell and 
 Progenitor Cell Lineages
For cancer to develop, a popula-
tion of continuously proliferating 
(self-renewing) cells must arise. For 
tumors containing a subpopulation 
of cancer stem cells, there are at 
least two ways that the cancer stem 
cells could have arisen. In the first, 
oncogenic mutations may inactivate 
the constraints on normal stem cell 
expansion, resulting in cancer stem 
cells that originated from normal 
stem cells. In the second, oncogenic 
mutations may allow transit-ampli-
fying cells to continue to proliferate 
without entering a postmitotic dif-
ferentiated state, thereby creating a 
pool of self-renewing cells in which 
further mutations can accumulate. 
This pool ultimately may give rise 
to cancer stem cells that originated 
from a more differentiated cell.
In the first case, oncogenic muta-
tions could arise in normal stem cells 
that cause defects in the mecha-
nisms that govern stem cell depend-
ence on the niche. For example, 
mutations could affect pathways that 
keep stem cells dependent on the 
niche for self-renewal. Alternatively, lsevier Inc.cancer stem cells could produce fac-
tors that recruit niche-forming cells 
into the tumor, resulting in an effec-
tive expansion of the niche itself (see 
Figure 1B). In another model, cancer 
stem cells could acquire the ability 
to activate self-renewal pathways 
in response to signals that do not 
normally regulate this process (see 
Figure 1C). There is also the pos-
sibility that cancer stem cells could 
activate intracellular signals normally 
activated by niche cells, or could 
express ligands usually expressed 
by niche-forming cells, or could con-
stitutively activate the receptors that 
respond to these ligands resulting in 
cell-autonomous activation of self-
renewal pathways (see Figure 1D).
In the second case, oncogenic 
mutations may arise that allow aber-
rant activation of the stem cell self-
renewal regulatory machinery in 
transit-amplifying cells (see Figure 
1E). This could imbue transit-ampli-
fying progenitor cells with stem-
cell-like properties, thus creating a 
pool of cells in which further genetic 
events could result in progression to 
a fully neoplastic state. For example, 
certain oncogenic mutations might 
destroy the control sequences that 
activate key differentiation genes, 
cell-cycle inhibitors, or cell death 
genes that negatively regulate self-
renewal. Alternatively, oncogenic 
mutations could cause failure of the 
mechanisms that normally limit tran-
sit-amplifying cell division capacity 
or that initiate postmitotic differen-
tiation (see Figure 1E). In addition, 
transit-amplifying cells may escape 
the controls that normally limit the 
number of cell divisions that they 
undergo before they enter a postmi-
totic state. Because the number of 
transit-amplifying cells is larger than 
the number of stem cells, mutations 
that allow the transit-amplifying cells 
to continue to proliferate rather than 
to terminally differentiate may be an 
important step in tumor formation.
Thus, many tumors may arise 
through a series of mutations that 
disrupt normal developmental path-
ways, culminating in the formation 
of cancer stem cells that then drive 
tumor growth. The particular onco-
genic mutations sustained by a stem 
cell as well as the specific interactions 
with the niche required for stem cell 
maintenance are likely to determine 
whether a cancer stem cell arises 
from a normal stem cell or from a 
transit-amplifying progenitor cell. Dif-
ferences between normal stem cells 
and cancer stem cells may reveal new 
targets for developing therapeutics 
to treat cancer more effectively. For 
example, if there are different molec-
ular interactions between the niche 
and normal and malignant stem cells, 
then it may be possible to find agents 
that specifically block self-renewal 
signals transmitted by the niche to 
cancer stem cells. Different mecha-
nisms may regulate the programmed 
decline in replication potential of tran-
sit-amplifying progenitor cells and the 
self-renewal of normal stem cells. A 
clearer understanding of these path-
ways and how they are disrupted in 
cancer stem cells may lead to more 
effective cancer therapies.
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